• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$62.51 -$0.59 (-0.94%)

REAL-TIME: Last trade at

Johnson & Johnson

NYSE:JNJ

Jump to this page for:

Related Resources

Chairman: Elan may get offer if Alzheimer drug data positive, Reuters says

5/25/2012 by Theflyonthewall.com

Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate)

5/25/2012 by PR Newswire

Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer

5/25/2012 by TheStreet.com

Johnson & Johnson: An Uncommon Opportunity

5/24/2012 by Seeking Alpha

Emerging Markets Exposure to Europe

5/24/2012 by CNBC Video

J&J loses key FDA panel vote on Xarelto

5/24/2012 by Fierce Biotech

J&J’s Blood Thinner Rejected by Panel for Expanded Use

5/24/2012 by Bloomberg.com

Johnson & Johnson Continues To Trade At Unprecedented Value

5/24/2012 by Seeking Alpha

Johnson & Johnson Group option implied volatility low

5/24/2012 by Theflyonthewall.com

Johnson & Johnson: Great Investment But Not For A Short-Term Price Rebound

5/23/2012 by Seeking Alpha

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

5/23/2012 by PR Newswire

Why Abbott Is A Buy After The Lawsuit

5/23/2012 by Seeking Alpha

How to Generate $1,000 Per Month in Dividends

5/23/2012 by InvestorPlace

BAND-AID® Brand Adhesive Bandages Transform The Healing Experience With Launch Of Its New Magic Vision Application Platform

5/23/2012 by PR Newswire

Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and Church & Dwight

5/23/2012 by PR Newswire

Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and Church & Dwight - Press Releases

5/23/2012 by Zacks Investment Research

FTC, Senate probing blocking of generic drug companies, Washington Post says

5/23/2012 by Theflyonthewall.com

Ex-Dividend Stocks: Johnson & Johnson, McGraw-Hill

5/23/2012 by TheStreet.com

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

5/23/2012 by PR Newswire

Berkshire Puts Money Back to Work in Equities

5/23/2012 by Morningstar

RobMarketsBlind's Latest Purchase - Voice of the People

5/22/2012 by Zacks Investment Research

Don't Miss Johnson & Johnson's Rebound

5/22/2012 by Seeking Alpha

Comparing 2 Dividend Plays In Healthcare

5/22/2012 by Seeking Alpha

Johnson & Johnson Now Poised To Hit $68 High

5/22/2012 by Seeking Alpha

Report Card: Johnson & Johnson And Selected Peers

5/22/2012 by Seeking Alpha

Johnson & Johnson 1 Of 5 Long-Term Prospects To Consider

5/22/2012 by Seeking Alpha

Analysis And Valuation: Johnson & Johnson, Pfizer, And Merck

5/22/2012 by Seeking Alpha

Johnson & Johnson Won't Stay Down Long - Here's A Bullish Income Play

5/22/2012 by Seeking Alpha

Johnson & Johnson's Simponi Helps Colitis Patients in Trial

5/22/2012 by BioSpace

Johnson & Johnson About To Put More Money In Your Pocket

5/22/2012 by Forbes

Prostate Cancer Companies Suffer When They Ignore Urologists

5/22/2012 by Minyanville

Catalysts That Could See Medtronic Jump After Earnings

5/21/2012 by Seeking Alpha

Johnson & Johnson Looks To Advance And Then Decline

5/21/2012 by Seeking Alpha

Janssen presents data from Phase 3 study of anti-TNF Simponi

5/21/2012 by Theflyonthewall.com

Food, Drugs, and MBAs

5/21/2012 by BusinessWeek

Johnson & Johnson Successfully Sues Chinese Distributor for Breach

5/21/2012 by BioSpace

What You Must Know Before Investing in Prostate Cancer Stocks

5/21/2012 by Minyanville

Johnson & Johnson management to meet with JPMorgan

5/21/2012 by Theflyonthewall.com

Research Reports for NASDAQ OMX, Juniper, MGM Resorts International, Nabors Industries, NetApp, Johnson & Johnson

5/21/2012 by PR Newswire

J&J-Bayer Blood Thinner Xarelto Is Recommended for Expanded Use

5/21/2012 by Bloomberg.com
See More Articles...